CIK 0001270073
ICPT INTERCEPT PHARMACEUTICALS, INC.
Insider trading from SEC Form 4. Last filing Nov 13, 2023.
In brief
INTERCEPT PHARMACEUTICALS, INC. (ICPT) has 18 SEC Form 4 filings on file from 17 insiders, the latest filed on Nov 13, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
17
with a Form 4 at this company
Signals
Open-market buys and sells at INTERCEPT PHARMACEUTICALS, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The newest 50 of 172 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 8, 2023 | M Michelle Berrey President, R&D and CMO | UTender of shares Common Stock | -28,349 | $19.00 | $539k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Luca Benatti director | UTender of shares Common Stock | -25,487 | $19.00 | $484k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jared Freedberg General Counsel | UTender of shares Common Stock | -22,681 | $19.00 | $431k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Srinivas Akkaraju director | UTender of shares Common Stock | -37,887 | $19.00 | $720k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Rocco Venezia Chief Accounting Officer | UTender of shares Common Stock | -10,782 | $19.00 | $205k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Mark Pruzanski director | UTender of shares Common Stock | -618,894 | $19.00 | $12M | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jerome Benedict Durso CEO | UTender of shares Common Stock | -51,815 | $19.00 | $984k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Keith Michael Gottesdiener director | UTender of shares Common Stock | -24,719 | $19.00 | $470k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Gino Santini director | UTender of shares Common Stock | -23,645 | $19.00 | $449k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Linda M Richardson EVP & Chief Commercial Officer | UTender of shares Common Stock | -16,706 | $19.00 | $317k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Dagmar Rosa-Bjorkeson director | UTender of shares Common Stock | -14,766 | $19.00 | $281k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Daniel Bradbury director | UTender of shares Common Stock | -23,548 | $19.00 | $447k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Paolo Fundaro director | UTender of shares Common Stock | -35,794 | $19.00 | $680k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | David A Ford Chief Human Resources Officer | UTender of shares Common Stock | -15,038 | $19.00 | $286k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Glenn Sblendorio director | UTender of shares Common Stock | -23,447 | $19.00 | $445k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Andrew Saik EVP & Chief Financial Officer | UTender of shares Common Stock | -23,021 | $19.00 | $437k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Nancy Miller-Rich director | UTender of shares Common Stock | -22,304 | $19.00 | $424k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jared Freedberg General Counsel | DDisposition to issuer Common Stock | -33,762 | $19.00 | $641k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Linda M Richardson EVP & Chief Commercial Officer | DDisposition to issuer Common Stock | -26,585 | $19.00 | $505k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Srinivas Akkaraju director | UTender of shares Common Stockindirect: See footnote | -640,688 | $19.00 | $12M | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Andrew Saik EVP & Chief Financial Officer | DDisposition to issuer Common Stock | -45,244 | $19.00 | $860k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | M Michelle Berrey President, R&D and CMO | DDisposition to issuer Common Stock | -51,790 | $19.00 | $984k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Paolo Fundaro director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Glenn Sblendorio director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jerome Benedict Durso CEO | DDisposition to issuer Common Stock | -102,825 | $19.00 | $2.0M | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Dagmar Rosa-Bjorkeson director | DDisposition to issuer Common Stock | -11,625 | $19.00 | $221k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Keith Michael Gottesdiener director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | David A Ford Chief Human Resources Officer | DDisposition to issuer Common Stock | -21,400 | $19.00 | $407k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Rocco Venezia Chief Accounting Officer | DDisposition to issuer Common Stock | -14,669 | $19.00 | $279k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Luca Benatti director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Gino Santini director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Nancy Miller-Rich director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Mark Pruzanski director | DDisposition to issuer Option to Purchase Common Stockderivative | -332 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Daniel Bradbury director | UTender of shares Common Stockindirect: See footnote | -7,812 | $19.00 | $148k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Daniel Bradbury director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Dagmar Rosa-Bjorkeson director | DDisposition to issuer Option to Purchase Common Stockderivative | -17,719 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | M Michelle Berrey President, R&D and CMO | DDisposition to issuer Option to Purchase Common Stockderivative | -17,600 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Mark Pruzanski director | DDisposition to issuer Option to Purchase Common Stockderivative | -5,401 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jared Freedberg General Counsel | DDisposition to issuer Option to Purchase Common Stockderivative | -17,600 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Jerome Benedict Durso CEO | DDisposition to issuer Option to Purchase Common Stockderivative | -60,900 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Linda M Richardson EVP & Chief Commercial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -17,600 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Glenn Sblendorio director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Srinivas Akkaraju director | DDisposition to issuer Common Stock | -8,111 | $19.00 | $154k | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Andrew Saik EVP & Chief Financial Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -17,600 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Paolo Fundaro director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Gino Santini director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | David A Ford Chief Human Resources Officer | DDisposition to issuer Option to Purchase Common Stockderivative | -11,300 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Keith Michael Gottesdiener director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Luca Benatti director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
| Nov 8, 2023 | Nancy Miller-Rich director | DDisposition to issuer Option to Purchase Common Stockderivative | -12,089 | - | - | 0 | Nov 13, 2023 |
50 of 172 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Srinivas Akkarajuowner, director
- Daniel Bradburydirector, chair, officer, owner
- Luca Benattidirector
- M Michelle BerreyPresident, R&D and CMO
- Jerome Benedict DursoCEO
- David A FordChief Human Resources Officer
- Jared FreedbergGeneral Counsel
- Paolo Fundarodirector
- Keith Michael Gottesdienerofficer, director
- Nancy Miller-Richdirector
- Mark Pruzanskidirector
- Dagmar Rosa-Bjorkesondirector
- Linda M RichardsonEVP & Chief Commercial Officer
- Gino Santinidirector
- Glenn Sblendoriodirector
- Andrew SaikEVP & Chief Financial Officer
- Rocco VeneziaChief Accounting Officer
Questions about ICPT
Answered from the filings on this page, as of the latest one.
Are insiders buying ICPT?
No. In the last 90 days no insider at INTERCEPT PHARMACEUTICALS, INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade ICPT on the open market?
No open-market trade has been scored at INTERCEPT PHARMACEUTICALS, INC.. The latest Form 4 on file was filed on Nov 13, 2023 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at INTERCEPT PHARMACEUTICALS, INC.?
17 people have filed a Form 4 at INTERCEPT PHARMACEUTICALS, INC., among them Srinivas Akkaraju (10% owner and director), Daniel Bradbury (director, chair and 10% owner), Luca Benatti (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.